AngioDynamics Reports Q2 Fiscal 2009 Results
Gross margin in the second quarter was 61.3%, consistent with the gross margin reported for the same period one year ago. Operating income increased in the second quarter
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XGross margin in the second quarter was 61.3%, consistent with the gross margin reported for the same period one year ago. Operating income increased in the second quarter
Specifically, the study will examine patients with tumors in the chest or abdomen and compare standard quantitative techniques, such as standard uptake value (SUV), with more advanced kinetic
Phillip C. Thomas stated, “Almost two years ago I joined Implant Sciences and was charged with the task of leading the Company through a major restructuring enabling the
Following the District Court’s decision in July 2007, requiring destruction of the infringing product and the entry of an injunction, Occlutech appealed the ruling and introduced its Figulla
McCool joins VisEn from Thermo Fisher Scientific, where he was the North American director of sales for the laboratory automation and cellular imaging businesses. Previously, he held senior
The Court issued a companion order that each case in the MDL will be dismissed with prejudice unless an individual plaintiff can establish his or her case survives